Each filer's latest filing for 03940C100 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Gilead Sciences, Inc. 13D/A | 100.0% |
4/28/2026
Event 4/28/2026
|
||
| BlackRock, Inc. 13G/A | 6.4% |
4/17/2025
Event 3/31/2025
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (9) | ||||
| T. Rowe Price Investment Management, Inc. 13G/A | 4.5% |
3/6/2026
Event 2/28/2026
|
||
|
Perceptive Advisors LLC
13G/A
|
4.5% |
8/14/2025
Event 6/30/2025
|
||
| Perceptive Advisors LLC | 4.5% | |||
| Joseph Edelman | 4.5% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 4.5% | |||
|
RA Capital Management, L.P.
13G/A
|
2.2% |
2/17/2026
Event 12/31/2025
|
||
| RA Capital Management, L.P. | 2.2% | |||
| Peter Kolchinsky | 2.2% | |||
| Rajeev Shah | 2.2% | |||
| RA Capital Healthcare Fund, L.P. | 2.2% | |||
|
FMR LLC
13G/A
|
0.5% |
3/6/2026
Event 2/27/2026
|
||
| FMR LLC | 0.5% | |||
| Abigail P. Johnson | 0.5% | |||
| Rami Elghandour 13D/A | 0% |
4/28/2026
Event 4/28/2026
|
||
|
New Enterprise Associates 15, L.P.
13D/A
|
0% |
4/30/2026
Event 4/28/2026
|
||
| New Enterprise Associates 15, L.P. | 0% | |||
| NEA Partners 15, L.P. | 0% | |||
| Nea 15 GP, LLC | 0% | |||
| Forest Baskett | 0% | |||
| Anthony A. Florence, Jr. | 0% | |||
| Mohamad H. Makhzoumi | 0% | |||
| Scott D. Sandell | 0% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
0% |
8/14/2026
Event 6/30/2026
|
||
| Paradigm BioCapital Advisors LP | 0% | |||
| Paradigm BioCapital Advisors GP LLC | 0% | |||
| Senai Asefaw, M.D. | 0% | |||
| Paradigm BioCapital International Fund Ltd. | 0% | |||
| Vanguard Group Inc 13G/A | 0% |
3/26/2026
Event 3/13/2026
|
||
|
Vestal Point Capital, LP
13G/A
|
0% |
5/15/2026
Event 3/31/2026
|
||
| Vestal Point Capital, LP | 0% | |||
| Ryan Wilder | 0% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 2 | 30.0 k | $3.43M |
| 2026 Q1 | 244 | 57.0 M | $6.52B |
| 2025 Q4 | 221 | 72.3 M | $4.71B |
| 2025 Q3 | 212 | 63.1 M | $5.18B |
| 2025 Q2 | 207 | 61.4 M | $4.01B |
| 2025 Q1 | 206 | 61.6 M | $4.04B |
| 2024 Q4 | 216 | 59.2 M | $4.54B |
| 2024 Q3 | 189 | 49.5 M | $4.13B |
| 2024 Q2 | 169 | 50.2 M | $2.77B |
| 2024 Q1 | 184 | 47.0 M | $3.27B |
| 2023 Q4 | 159 | 46.7 M | $2.59B |
| 2023 Q3 | 137 | 47.6 M | $1.71B |
| 2023 Q2 | 140 | 48.1 M | $1.52B |
| 2023 Q1 | 120 | 45.6 M | $1.40B |
| 2022 Q4 | 127 | 41.9 M | $1.30B |
| 2022 Q3 | 75 | 41.7 M | $782M |
| 2022 Q2 | 69 | 34.9 M | $622M |
| 2022 Q1 | 50 | 26.9 M | $358M |